Featured Research

from universities, journals, and other organizations

Revisiting the David Nutt debate: Is it possible to rank different drugs by the harm they cause?

Date:
September 6, 2011
Source:
Wiley-Blackwell
Summary:
The scientific and political worlds were transfixed in late 2009 when UK drugs advisor Dr. David Nutt was sacked by Home Secretary Alan Johnson for his controversial views on the harmfulness of different drugs and the lack of evidence behind current drug policy, views first publicized in a Lancet report in 2007. Scientists at the time were unanimous that scholarly research such as Nutt's should not be subject to political attack, but a new scholarly article points out a more rational basis for criticizing Nutt's work on the harmfulness of drugs: it is scientifically flawed, the article's authors argue.

The scientific and political worlds were transfixed in late 2009 when UK drugs advisor Dr. David Nutt was sacked by Home Secretary Alan Johnson for his controversial views on the harmfulness of different drugs and the lack of evidence behind current drug policy, views first publicised in a Lancet report in 2007.1 Scientists at the time were unanimous that scholarly research such as Nutt's should not be subject to political attack, but a new article in the scholarly journal Addiction points out a more rational basis for criticizing Nutt's work on the harmfulness of drugs: it is scientifically flawed, the articles author's argue.

Related Articles


American researchers Jonathan Caulkins, Peter Reuter, and Carolyn Coulson argue that Nutt erred by assuming that drug-related harms can be reduced to a single dimension. Most such rankings combine individual harms and harms to society. But national drug policies aim to reduce harm to society, so combined scores may be misleading. Furthermore, it is not for scientists alone to decide the relative weights society should place on such disparate drug-related harms as dependence, overdose death, and corruption. Caulkins and colleagues also argue that even perfect ratings of substances' current harm to society would not be useful, because harm is governed by the interaction between substance and policy; it is not a property of the chemical alone. Policymakers need analytical tools that show the likely changes in different types of harm associated with each change in drug policy.

Addiction hosts a spirited international debate about these critiques, including a response from Dr. Nutt himself.

Canadian researchers Benedikt Fischer and Perry Kendall argue that there is no benefit to categorically knocking down the work of Nutt and his colleagues when current global drug control policy pays scientific evidence no heed. The primary problem at hand is to get governments to pay attention to the evidence for drug policies, not to develop more complex rankings that will be ignored. Fischer and Kendall state, "If we assume public health and welfare should be guiding principles for substance control policy, we would not expect to see the third most commonly used drug (cannabis) to be scheduled and regulated alongside drugs like heroin and cocaine, while alcohol and tobacco are not only legally available, but are openly traded and lead to thousands of cases of deaths and injuries each year."

This view is supported by Norwegian researcher Ingeborg Rossow. She argues that Norwegian policymakers' views reflect those of the general public: illegal substances constitute a larger problem than alcohol, which justifies strict control of illegal drugs and liberalization of alcohol control. Addiction researchers know that legal substances (alcohol, tobacco, prescription drugs) are as much a problem as illegal substances, but getting the public to recognize this fact is difficult. Publicising reports on the relative size of harms from legal and illegal substances may help to change public opinion.

Australian researcher Robin Room argues that all national drug schedules are based on two outdated, pharmacologically-based international drug treaties from 1961 and 1971. By ranking drugs in the light of changes in knowledge and understanding since then, Nutt and colleagues have "started a debate which is long overdue."

"The priority of the debate" Room argues, "should be on the official schedules and what to do about them."

Isidore Obot, a Nigerian researcher, embraces the idea of developing more complex policy tools, because more refined ranking systems will produce more useful information for policymakers. The value of the model developed by Nutt and colleagues lies in the improvements future researchers will make to it.

David Nutt's defence is expressed in his Voltairian title, "Let not the best be the enemy of the good." Nutt accepts that the 2007 harm-ranking model is imperfect but argues that it is nonetheless a good attempt to use scientific evidence in drug policy. Says Nutt: "we have provided the best currently available analysis of an extremely complex multifaceted data set. It ain't perfect but is nevertheless good enough to be useful." Nutt also explains that his simplified look at drug harms provides policymakers with a tool of the type they use: "All decisions regarding drug classifications resolve harms into a single scale point for each drug, so people, particularly politicians, are used to making and working with such estimations."

Caulkins, Reuter, and Coulson respond by restating that the current methods of ranking drugs by harm are conceptually and methodologically unsound. Defending them on the grounds that that simplification is required is equally unsound. We need better methods for understanding the complex network of individual and aggregate harms. "[If] the public has trouble grasping multi-dimensional scales, that should be seen as a hurdle to overcome, not a restraint that needs to be accepted."

The final word should perhaps go to Fischer and Kendall, who argue that any country that uses these admittedly flawed and limited harm scales to inform public policy will experience a "quantum leap of progress" toward evidence-based drug policy. They state that "The benefits from grounding drug control policy in Nutt et al.'s harm scales could be expected to be tangible and last until well after their critics have revised and improved them."


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal References:

  1. Jonathan P. Caulkins, Peter Reuter, Carolyn Coulson. Basing drug scheduling decisions on scientific ranking of harmfulness: false promise from false premises. Addiction, 2011; DOI: 10.1111/j.1360-0443.2011.03461.x
  2. David Nutt, Leslie A King, William Saulsbury, Colin Blakemore. Development of a rational scale to assess the harm of drugs of potential misuse. The Lancet, 2007; 369 (9566): 1047 DOI: 10.1016/S0140-6736(07)60464-4

Cite This Page:

Wiley-Blackwell. "Revisiting the David Nutt debate: Is it possible to rank different drugs by the harm they cause?." ScienceDaily. ScienceDaily, 6 September 2011. <www.sciencedaily.com/releases/2011/09/110906121953.htm>.
Wiley-Blackwell. (2011, September 6). Revisiting the David Nutt debate: Is it possible to rank different drugs by the harm they cause?. ScienceDaily. Retrieved November 1, 2014 from www.sciencedaily.com/releases/2011/09/110906121953.htm
Wiley-Blackwell. "Revisiting the David Nutt debate: Is it possible to rank different drugs by the harm they cause?." ScienceDaily. www.sciencedaily.com/releases/2011/09/110906121953.htm (accessed November 1, 2014).

Share This



More Health & Medicine News

Saturday, November 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Melafind: Spotting Melanoma Without a Biopsy

Melafind: Spotting Melanoma Without a Biopsy

Ivanhoe (Oct. 31, 2014) The MelaFind device is a pain-free way to check suspicious moles for melanoma, without the need for a biopsy. Video provided by Ivanhoe
Powered by NewsLook.com
Battling Multiple Myeloma

Battling Multiple Myeloma

Ivanhoe (Oct. 31, 2014) The answer isn’t always found in new drugs – repurposing an ‘old’ drug that could mean better multiple myeloma treatment, and hope. Video provided by Ivanhoe
Powered by NewsLook.com
Chronic Inflammation and Prostate Cancer

Chronic Inflammation and Prostate Cancer

Ivanhoe (Oct. 31, 2014) New information that is linking chronic inflammation in the prostate and prostate cancer, which may help doctors and patients prevent cancer in the future. Video provided by Ivanhoe
Powered by NewsLook.com
Sickle Cell: Stopping Kids’ Silent Strokes

Sickle Cell: Stopping Kids’ Silent Strokes

Ivanhoe (Oct. 31, 2014) Blood transfusions are proving crucial to young sickle cell patients by helping prevent strokes, even when there is no outward sign of brain injury. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins